Zacks Investment Research
30 Jul 2026, 23:06 UTC · 3d ago
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
30 Jul 2026, 23:06 UTC · 3d ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Myriad Genetics (MYGN) reported a quarterly loss of $0.25 per share, significantly missing the Zacks Consensus Estimate of a $0.03 loss. — A massive earnings miss of -733.33% relative to estimates typically triggers a sharp negative price reaction.
-0.80Myriad Genetics reported quarterly revenues of $190.7 million, missing the Zacks Consensus Estimate by 7.12% and declining from $213.1 million a year ago. — Declining year-over-year revenue combined with a miss on expectations suggests weakening fundamental demand.
-0.60Myriad Genetics currently holds a Zacks Rank #3 (Hold) based on the trend of earnings estimate revisions. — A 'Hold' rating indicates a neutral outlook with no strong immediate catalyst for a trend reversal.
+0.00Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company reported a significantly larger quarterly loss than expected, missed revenue estimates, and has underperformed the S&P 500.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
2h ago
